CoChat

Structural basis of 3′-tRNA maturation by the human mitochondrial RNAse Z complex

Open access
Gesé, Genís Valentín, Martin Hällberg, B. · 2024 · The EMBO Journal

Preprint — published as 10.1038/s44318-024-00297-w

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Human mitochondrial tRNA maturation is essential for cellular energy production, yet the underlying mechanisms remain only partially understood. Here, we present several cryo-EM structures of the mitochondrial RNase Z complex (ELAC2/SDR5C1/TRMT10C) bound to different maturation states of mitochondrial tRNA His , showing the molecular basis for tRNA-substrate selection and catalysis. Our structural insights provide a molecular rationale for the 5′-to-3′ tRNA processing order in mitochondria, the 3′-CCA antideterminant effect, and the basis for sequence-independent recognition of mitochondrial tRNA substrates. Furthermore, the study links mutations in ELAC2 to clinically relevant mitochondrial diseases, offering a deeper understanding of the molecular defects contributing to these conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2024.05.14.593974

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structure of human mitochondrial RNase Z. (A) Domain architecture of the human mitochondrial RNase Z components. The N-terminal (NTD) and C-terminal (CTD) domains of ELAC2 are shown in dark and light purple, respectively. MBL1 and MBL2, which are the metallo-β-lactamase folds, and the exosite insertion are indicated with dotted lines. TRMT10C is shown in blue, with the NTD highlighted in cyan. MTS, mitochondrial targeting sequence. Unmodelled regions are in white. (B) The mt-tRNA precursor consists of tRNAHis (red) and tRNASer(AGY) (gray line), of which the latter has been cleaved off in the ternary product structure. Base-paired nucleotides are in red circles, and non-base-paired ones are in white circles. The anticodon triplet is in gray circles. Canonical tRNA numbering is indicated (Giegé et al, 2012) and is used throughout the text (the correspondence with nucleotide numbers in mitochondrial tRNAHis, which was used in the PDB deposited structures, is shown in Appendix Table S1). (C, D) Composite cryo-EM density (C) and cartoon representation (D) of the RNase Z complex. Colored as in A. The four SDR5C1 subunits are shown in different shades of gray. The ELAC2 active site is marked with a yellow star.
Figure 1 Structure of human mitochondrial RNase Z. (A) Domain architecture of the human mitochondrial RNase Z components. The N-terminal (NTD) and C-terminal (CTD) domains of ELAC2 are shown in dark and light purple, respectively. MBL1 and MBL2, which are the metallo-β-lactamase folds, and the exosite insertion are indicated with dotted lines. TRMT10C is shown in blue, with the NTD highlighted in cyan. MTS, mitochondrial targeting sequence. Unmodelled regions are in white. (B) The mt-tRNA precursor consists of tRNAHis (red) and tRNASer(AGY) (gray line), of which the latter has been cleaved off in the ternary product structure. Base-paired nucleotides are in red circles, and non-base-paired ones are in white circles. The anticodon triplet is in gray circles. Canonical tRNA numbering is indicated (Giegé et al, 2012) and is used throughout the text (the correspondence with nucleotide numbers in mitochondrial tRNAHis, which was used in the PDB deposited structures, is shown in Appendix Table S1). (C, D) Composite cryo-EM density (C) and cartoon representation (D) of the RNase Z complex. Colored as in A. The four SDR5C1 subunits are shown in different shades of gray. The ELAC2 active site is marked with a yellow star.CC BY · PubMed Central
Figure EV1 The TRMT10C structure (related to Fig. 1). (A) ELAC2 activity in the presence and absence of the TRMT10C/SDR5C1 platform. (B) Cryo-EM density of particles containing two TRMT10C subunits. The 4xSDR5C1 platform offers two mt-tRNA/TRMT10C binding sites. The platform has a vertical and a horizontal twofold symmetry axis. Consequently, it supports two mt-tRNA/TRMT10C subcomplexes, which can be in two different but equivalent orientations (left and right panels). The 4xSDR5C1 are colored in different shades of gray; TRMT10C is colored in dark blue with the NTD highlighted in light blue; the mt-tRNA is in red. ELAC2 density is not visible due to the low occupancy. Source data are available online for this figure.
Figure EV1 The TRMT10C structure (related to Fig. 1). (A) ELAC2 activity in the presence and absence of the TRMT10C/SDR5C1 platform. (B) Cryo-EM density of particles containing two TRMT10C subunits. The 4xSDR5C1 platform offers two mt-tRNA/TRMT10C binding sites. The platform has a vertical and a horizontal twofold symmetry axis. Consequently, it supports two mt-tRNA/TRMT10C subcomplexes, which can be in two different but equivalent orientations (left and right panels). The 4xSDR5C1 are colored in different shades of gray; TRMT10C is colored in dark blue with the NTD highlighted in light blue; the mt-tRNA is in red. ELAC2 density is not visible due to the low occupancy. Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Stabilization of the tRNA fold by TRMT10C. (A) TRMT10C (white) wraps around the mt-tRNAHis anticodon stem and D arm to stabilize the cloverleaf fold. The nucleotide numbers forming the T loop are indicated for comparison with those in (B, C). (B, C) Molecular interactions of TRMT10C with the T loop (B) and the D arm (C). The views have been rotated for easier visualization.
Figure 2 Stabilization of the tRNA fold by TRMT10C. (A) TRMT10C (white) wraps around the mt-tRNAHis anticodon stem and D arm to stabilize the cloverleaf fold. The nucleotide numbers forming the T loop are indicated for comparison with those in (B, C). (B, C) Molecular interactions of TRMT10C with the T loop (B) and the D arm (C). The views have been rotated for easier visualization.CC BY · PubMed Central
Figure 3 Interaction of ELAC2 with the precursor mt-tRNAHis. (A) Overview of the human mitochondrial RNase Z complex. The boxes represent the insets for (B–E). (B) Contacts between the ELAC2 exosite, the T loop, and the TRMT10C N-terminal domain. (C) Contacts between the ELAC2 C-terminal helix, the TRMT10C, and the acceptor stem. (D) Recognition of the 5′-end of the mt-tRNA. Only the α-phosphate of G1 is shown since natural ELAC2 substrates carry a 5′-monophosphate. (E) Interaction of ELAC2 with the acceptor stem/T arm groove.
Figure 3 Interaction of ELAC2 with the precursor mt-tRNAHis. (A) Overview of the human mitochondrial RNase Z complex. The boxes represent the insets for (B–E). (B) Contacts between the ELAC2 exosite, the T loop, and the TRMT10C N-terminal domain. (C) Contacts between the ELAC2 C-terminal helix, the TRMT10C, and the acceptor stem. (D) Recognition of the 5′-end of the mt-tRNA. Only the α-phosphate of G1 is shown since natural ELAC2 substrates carry a 5′-monophosphate. (E) Interaction of ELAC2 with the acceptor stem/T arm groove.CC BY · PubMed Central
Figure EV2 TRMT10C/SDR5C1 interactions with ELAC2 and PRORP (related to Fig. 2). (A) ELAC2 cleavage of the mt-tRNAHis-GAG precursor in the absence of TRMT10C/SDR5C1, or with the mutations V256E_L257E that affect residues interacting with TRMT10C. (B) TRMT10C NTD interacts with ELAC2 (RNase Z, left panel) and PRORP (RNase P, right panel) in the T loop region. (C) The ELAC2 C-terminal helix would collide with a 5′ extension on the mt-tRNA precursor (yellow circle). To make this figure, the mt-tRNA precursor in RNase Z was replaced with the RNase P one (mt-tRNATyr), which has a 2-nucleotide 5′-extension. For this, The RNase Z structure was superimposed on the RNase P structure (Bhatta et al, 2021; PDB 7ONU), using TRMT10C as a reference. Source data are available online for this figure.
Figure EV2 TRMT10C/SDR5C1 interactions with ELAC2 and PRORP (related to Fig. 2). (A) ELAC2 cleavage of the mt-tRNAHis-GAG precursor in the absence of TRMT10C/SDR5C1, or with the mutations V256E_L257E that affect residues interacting with TRMT10C. (B) TRMT10C NTD interacts with ELAC2 (RNase Z, left panel) and PRORP (RNase P, right panel) in the T loop region. (C) The ELAC2 C-terminal helix would collide with a 5′ extension on the mt-tRNA precursor (yellow circle). To make this figure, the mt-tRNA precursor in RNase Z was replaced with the RNase P one (mt-tRNATyr), which has a 2-nucleotide 5′-extension. For this, The RNase Z structure was superimposed on the RNase P structure (Bhatta et al, 2021; PDB 7ONU), using TRMT10C as a reference. Source data are available online for this figure.CC BY · PubMed Central
Figure 4 Interactions around the tRNA scissile bond and the ELAC2 HFSQRY motif. (A) In the RNAse Z-HS structure, the 3′-oxygen interacts with a Zn2+ after the 3′-trailer is removed (B) Composite cryo-EM density of the human mitochondrial RNase Z bound to the mt-tRNAHis-Ser(AGY) precursor, carrying the ELAC2 mutation H548A. The part of the map corresponding to mt-tRNASer(AGY) moiety was gaussian-filtered with a B-factor of 600 in UCSF ChimeraX. Colored as in Fig. 1. (C) The RNase ZH548A-HS structure shows how the scissile bond is well-oriented for catalysis assisted by K700. The missing Zn2+ due to the H548A mutation is shown by a transparent circle based on the RNase Z-HS structure. In the RNase Z-HS structure, the 3′-oxygen interacts with a Zn2+ after the 3′-trailer is removed.
Figure 4 Interactions around the tRNA scissile bond and the ELAC2 HFSQRY motif. (A) In the RNAse Z-HS structure, the 3′-oxygen interacts with a Zn2+ after the 3′-trailer is removed (B) Composite cryo-EM density of the human mitochondrial RNase Z bound to the mt-tRNAHis-Ser(AGY) precursor, carrying the ELAC2 mutation H548A. The part of the map corresponding to mt-tRNASer(AGY) moiety was gaussian-filtered with a B-factor of 600 in UCSF ChimeraX. Colored as in Fig. 1. (C) The RNase ZH548A-HS structure shows how the scissile bond is well-oriented for catalysis assisted by K700. The missing Zn2+ due to the H548A mutation is shown by a transparent circle based on the RNase Z-HS structure. In the RNase Z-HS structure, the 3′-oxygen interacts with a Zn2+ after the 3′-trailer is removed.CC BY · PubMed Central
Figure EV3 Pivoting of ELAC2 on the mt-tRNA (related to Fig. 3). (A) ELAC2 pivots on the mt-tRNA to reach the catalytic position. The RNase Z-HS structure is at the forefront. The outline of the RNase ZH548A-HS and the RNase Z-HCCA structures are shown to highlight the movement of ELAC2. ELAC2 is colored in light and dark purple for the CTD and NTD, respectively, while TRMT10C is in blue, and the four SDR5C1 subunits are in shades of gray. (B) Cryo-EM composite maps of RNase Z bound to the three different tRNA precursors, aligned on TRMT10C. The cryo-EM density of the mt-tRNASer(AGY) moiety has been Gaussian-filtered in UCSF ChimeraX with a B-factor of 600 for better visualization. To visualize the ELAC2 movement, notice the changes in the gap with TRTM10C. (C) Cryo-EM density for the mt-tRNASer(AGY) in RNase ZH548A-HS structure. The density, for which it was not possible to create an atomic model, displaces the G157-P157 loop compared with the RNase Z-HS structure (superposed in white). (D) Comparison with the B. subtilis RNase Z bound to precursor tRNA. In B. Subtilis (white), U1 inserts into a pocket and helps position the scissile bond. In RNase ZH548A-HS, G1 does not bind in the pocket as it is partially occluded by L126. The B. Subtilis Zn2+ are shown as white spheres. The RNase ZH548A-HS missing Zn2+ is drawn based on the RNase Z-HS structure.
Figure EV3 Pivoting of ELAC2 on the mt-tRNA (related to Fig. 3). (A) ELAC2 pivots on the mt-tRNA to reach the catalytic position. The RNase Z-HS structure is at the forefront. The outline of the RNase ZH548A-HS and the RNase Z-HCCA structures are shown to highlight the movement of ELAC2. ELAC2 is colored in light and dark purple for the CTD and NTD, respectively, while TRMT10C is in blue, and the four SDR5C1 subunits are in shades of gray. (B) Cryo-EM composite maps of RNase Z bound to the three different tRNA precursors, aligned on TRMT10C. The cryo-EM density of the mt-tRNASer(AGY) moiety has been Gaussian-filtered in UCSF ChimeraX with a B-factor of 600 for better visualization. To visualize the ELAC2 movement, notice the changes in the gap with TRTM10C. (C) Cryo-EM density for the mt-tRNASer(AGY) in RNase ZH548A-HS structure. The density, for which it was not possible to create an atomic model, displaces the G157-P157 loop compared with the RNase Z-HS structure (superposed in white). (D) Comparison with the B. subtilis RNase Z bound to precursor tRNA. In B. Subtilis (white), U1 inserts into a pocket and helps position the scissile bond. In RNase ZH548A-HS, G1 does not bind in the pocket as it is partially occluded by L126. The B. Subtilis Zn2+ are shown as white spheres. The RNase ZH548A-HS missing Zn2+ is drawn based on the RNase Z-HS structure.CC BY · PubMed Central
Figure 5 Structural basis for 3′-CCA discrimination. (A) ELAC2 dilution series on 200 nM mt-tRNAHis-GAG or mt-tRNAHis-CCA and 800 nM TRMT10C/SDR5C1 was analyzed using a TBE-UREA PAGE. Representative gel image of technical triplicates and biological duplicates for WT ELAC2. (B) Composite cryo-EM density of human mitochondrial RNase Z bound to the mt-tRNAHis-CCA. Colored as in Fig. 1. The density for the 3′-CCA trailer is indicated with a yellow circle. (C) The 3′-CCA occupies the active site channel of ELAC2. The mt-tRNAHis 3′-end is 13.4 Å away from the catalytic Zn2+ (gray spheres). (D) Interactions of C1CCA with ELAC2 S490 and S726. (E) Interactions of C2CCA with Q92 and T127. The hydrogen atoms were added in ChimeraX to visualize the H-bonding interactions. (F) Comparison with the tRNAThr precursor bound to the B. subtilis RNase Z (Pellegrini et al, 2012), which shows the interactions required for catalysis. The phosphate oxygens coordinate one Zn2+ ion each. The hydrolyzing water molecule (red sphere) is positioned by D550. In RNase Z-HCCA, the backbone adopts a different conformation, which is unsuitable for catalysis. Source data are available online for this figure.
Figure 5 Structural basis for 3′-CCA discrimination. (A) ELAC2 dilution series on 200 nM mt-tRNAHis-GAG or mt-tRNAHis-CCA and 800 nM TRMT10C/SDR5C1 was analyzed using a TBE-UREA PAGE. Representative gel image of technical triplicates and biological duplicates for WT ELAC2. (B) Composite cryo-EM density of human mitochondrial RNase Z bound to the mt-tRNAHis-CCA. Colored as in Fig. 1. The density for the 3′-CCA trailer is indicated with a yellow circle. (C) The 3′-CCA occupies the active site channel of ELAC2. The mt-tRNAHis 3′-end is 13.4 Å away from the catalytic Zn2+ (gray spheres). (D) Interactions of C1CCA with ELAC2 S490 and S726. (E) Interactions of C2CCA with Q92 and T127. The hydrogen atoms were added in ChimeraX to visualize the H-bonding interactions. (F) Comparison with the tRNAThr precursor bound to the B. subtilis RNase Z (Pellegrini et al, 2012), which shows the interactions required for catalysis. The phosphate oxygens coordinate one Zn2+ ion each. The hydrolyzing water molecule (red sphere) is positioned by D550. In RNase Z-HCCA, the backbone adopts a different conformation, which is unsuitable for catalysis. Source data are available online for this figure.CC BY · PubMed Central
Figure EV4 Selected ELAC2 mutations involved in hypertrophic cardiomyopathy do not impair the 3’-CCA antidetermination (related to Fig. 5). (A) Interactions around the tRNA 3′-end or the 3′-CCA tail involve the same ELAC2 residues. Two parallel black lines indicate π-stacking. Selected electrostatic interactions are indicated with gray dotted lines. (B) Selected clinical mutations near the ELAC2 active site that only mildly impact the catalytic activity, namely T520I (Haack et al, 2013), F154L (Haack et al, 2013), and G132R (Paucar et al, 2018). Mutations are shown in dark and light purple for the NTD and the CTD of ELAC2, respectively. The rest of ELAC2 is in gray, and the tRNA is in red. (C) Cleavage activity of the ELAC2 mutants on tRNAHis-CCA assessed by TBE-UREA PAGE. None of the mutations significantly affects the 3′-CCA antideterminant effect. The WT panel is the same as in Fig. 5A, shown here for an easier side-to-side comparison. Representative gel images of technical triplicates and biological duplicates for WT. Source data are available online for this figure.
Figure EV4 Selected ELAC2 mutations involved in hypertrophic cardiomyopathy do not impair the 3’-CCA antidetermination (related to Fig. 5). (A) Interactions around the tRNA 3′-end or the 3′-CCA tail involve the same ELAC2 residues. Two parallel black lines indicate π-stacking. Selected electrostatic interactions are indicated with gray dotted lines. (B) Selected clinical mutations near the ELAC2 active site that only mildly impact the catalytic activity, namely T520I (Haack et al, 2013), F154L (Haack et al, 2013), and G132R (Paucar et al, 2018). Mutations are shown in dark and light purple for the NTD and the CTD of ELAC2, respectively. The rest of ELAC2 is in gray, and the tRNA is in red. (C) Cleavage activity of the ELAC2 mutants on tRNAHis-CCA assessed by TBE-UREA PAGE. None of the mutations significantly affects the 3′-CCA antideterminant effect. The WT panel is the same as in Fig. 5A, shown here for an easier side-to-side comparison. Representative gel images of technical triplicates and biological duplicates for WT. Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 4

  1. Altman, S. , & Kirsebom, L. (1999). Ribonuclease P: The RNA world Second edition. https://www.semanticscholar.org/paper/Ribonuclease-P-%3A-The-RNA-world-Second-edition-Altman-Kirsebom/7c65602bd6e6114220ebc68d475b3d56937f25c1
  2. 10.1101/2024.04.04.588063 · doi:10.1101/2024.04.04.588063
  3. 10.1101/2023.12.19.572246 · DOI · Paper page
  4. 10.1101/2020.04.08.032466 · DOI

Metadata

Authors
Gesé, G. V., & Martin Hällberg, B.
Affiliations
Karolinska Institutet (SE)
Venue
The EMBO Journal
Publisher
openRxiv
Published
2024-05-14
Volume
43
Issue
24
Pages
6573-6590
ISSN
0261-4189 (ISSN-L)
OpenAlex
W4404162686
Cited by
23
References
43
Citations by year
2026: 12 · 2025: 9 · 2024: 2
FWCI
3.13
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The EMBO Journal (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Karolinska Institutet
  • Knut och Alice Wallenbergs Stiftelse (2017.0080, 2018-0080)
  • Vetenskapsrådet (2022-02326, 2017.0080, 2018-, 2018-03808)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords
ELAC2, tRNAHis, mitochondrial disease, cryo-EM structure
MeSH terms
RNA, Mitochondrial, Endoribonucleases, Humans, Methyltransferases, Mitochondria, Models, Molecular, Mutation, Neoplasm Proteins, RNA Processing, Post-Transcriptional, RNA, Transfer, RNA, Transfer, His, Cryoelectron Microscopy, Mitochondrial Proteins, Mitochondrial Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural basis of 3′-tRNA maturation by the human mitochondrial RNAse Z complex. https://app.cochat.ai/papers/10.1101/2024.05.14.593974
The paper
Gesé, G. V., & Martin Hällberg, B. (2024). Structural basis of 3′-tRNA maturation by the human mitochondrial RNAse Z complex. The EMBO Journal. https://doi.org/10.1101/2024.05.14.593974

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.